For Research Use Only · Not For Human or Veterinary Use · Not FDA-Approved

— Research monograph

RT3

triple agonistGIP/GLP-1/glucagon agonist

The first triple GIP/GLP-1/glucagon receptor agonist to clear Phase 2 trials.

Updated

Class
Triple agonist at GIP, GLP-1, and glucagon receptors (synthetic peptide)
Half-life (research)
~6 days (early clinical pharmacokinetic reports).
Origin
First publicly characterized by Coskun et al. in 2022 as the next-generation evolution of the dual-incretin concept embodied in TZ2.
Solubility
Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.

What is RT3?

RT3 is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation.

The compound is currently in late-stage clinical investigation for obesity and type 2 diabetes. Public literature is concentrated in Phase 1–2 trial reports and preclinical pharmacology.

How does RT3 work?

Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models.

Research applications

  • Triple-incretin pharmacology
  • Energy expenditure research
  • Comparative incretin-agonist studies
  • Metabolic flux models

RT3 at Merit

Form & storage

RT3 ships as a sealed, lyophilized (freeze-dried) powder. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.

Frequently asked questions

What is RT3?

RT3 is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.

How does RT3 work?

Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.

What is the half-life of RT3?

~6 days (early clinical pharmacokinetic reports). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.

Is Merit RT3 for human use?

No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.

Is RT3 FDA-approved?

RT3 is not FDA-approved; it is investigational. Supplied for research use only.

How is each batch of RT3 tested?

Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: RT3 10 mg, July 2026 batch, 99.13% purity (meritsciences.com/coa/COA-2026-49Y4L7); RT3 30 mg, July 2026 batch, 99.27% purity (meritsciences.com/coa/COA-2026-REQNW5).

References

  1. Coskun T, Urva S, Roell WC, et al. Cell Metabolism, 2022 · PMID 35985340
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine, 2023 · PMID 37366315
  3. Rosenstock J, Frias J, Jastreboff AM, et al. The Lancet, 2023 · PMID 37385280

For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.